Unraveling the tumor-initiating cells in hepatocellular carcinoma

IF 48.8 1区医学 Q1 CELL BIOLOGY

Cancer Cell Pub Date : 2024-11-21 DOI:10.1016/j.ccell.2024.10.018

Yu Man Tsui, Daniel Wai-Hung Ho, Irene Oi-Lin Ng

引用次数: 0

Abstract

Aggressive features of hepatocellular carcinoma (HCC) are highly related to liver tumor-initiating cells (TICs), which are heterogeneous and plastic. In this issue of Cancer Cell, Yang et al. reveal the ability of CD49f-high TICs in shaping the tumor immunosuppressive microenvironment in HCC.

查看原文本刊更多论文

揭示肝细胞癌中的肿瘤启动细胞

肝细胞癌（HCC）的侵袭性特征与肝脏肿瘤启动细胞（TICs）高度相关，而TICs具有异质性和可塑性。在本期《癌细胞》（Cancer Cell）杂志上，Yang 等人揭示了 CD49f 高的 TIC 在 HCC 中塑造肿瘤免疫抑制微环境的能力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Cell 医学-肿瘤学

CiteScore

55.20

自引率

1.20%

发文量

179

审稿时长

4-8 weeks

期刊介绍： Cancer Cell is a journal that focuses on promoting major advances in cancer research and oncology. The primary criteria for considering manuscripts are as follows: Major advances: Manuscripts should provide significant advancements in answering important questions related to naturally occurring cancers. Translational research: The journal welcomes translational research, which involves the application of basic scientific findings to human health and clinical practice. Clinical investigations: Cancer Cell is interested in publishing clinical investigations that contribute to establishing new paradigms in the treatment, diagnosis, or prevention of cancers. Insights into cancer biology: The journal values clinical investigations that provide important insights into cancer biology beyond what has been revealed by preclinical studies. Mechanism-based proof-of-principle studies: Cancer Cell encourages the publication of mechanism-based proof-of-principle clinical studies, which demonstrate the feasibility of a specific therapeutic approach or diagnostic test.